Metallo-β-lactamase (MBL)-producing carbapenemase-producing Enterobacterales (CPE) present significant therapeutic challenges due to resistance to most β-lactam agents, including carbapenems. Aztreonam combined with avibactam (ATM/AVI) provides a promising treatment strategy, but standardized antimicrobial susceptibility testing (AST) methods remain limited. This study evaluated the performance of the MTS™ ATM/AVI gradient strip (Liofilchem) with the CLSI-recommended ceftazidime-avibactam plus aztreonam (CZA/ATM) broth disk elution (BDE) method in 36 CPE and 9 Stenotrophomonas maltophilia clinical isolates. Categorical agreement between these methods was 97.2 % for CPE and 88.9 % for S. maltophilia. Whole-genome sequencing was used for discrepancy analysis. Based on accuracy, reproducibility, and ease of use, the ATM/AVI gradient strip was selected as the preferred method for clinical laboratory testing.
Treatment of Mycobacterium tuberculosis requires multi-drug regimens, and resistance to any individual antibiotic can compromise outcomes. For slow-growing organisms like M. tuberculosis, rapid detection of resistance-conferring mutations enables timely initiation of effective therapy. Conversely, confirming wild-type status in resistance-associated genes supports confidence in standard regimens. We developed an amplicon-based next generation sequencing (amplicon tNGS) assay on the Illumina platform targeting eight genes linked to resistance to isoniazid, rifampin, ethambutol, pyrazinamide, and fluoroquinolones. Sequencing results were analyzed using a custom bioinformatics pipeline. Forty-seven samples were used for assay development, and 37 additional samples underwent post-implementation clinical validation. Compared to whole genome sequencing (WGS), amplicon tNGS demonstrated 97.7% sensitivity, 98.9% specificity, and 98.7% overall accuracy for variant detection in targeted regions. Resistance prediction showed 79.3% concordance with WGS; discrepancies were primarily due to mutations outside of target regions. Among post-implementation samples, 27/37 passed quality metrics for all targets, with 95.7% concordance between amplicon tNGS results and final susceptibility results. This assay is now in use in our laboratory and offers significantly faster turnaround than both WGS and phenotypic methods on cultured isolates, enabling more rapid, informed treatment decisions for tuberculosis patients.
Introduction: Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing minimum inhibitory concentration (MIC) distributions for ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods: MIC data for AmpC isolates between November 2019 to October 2024 were retrieved (BD Epicenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g., respiratory, wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2A-1). Descriptive statistics were computed and compared between moderate-risk AmpC inducers (MRAC) versus low-risk AmpC inducers (LRAC). Results: 5,809 isolates were analyzed, with 3,646 (62.8%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin-tazobactam, cefepime, and meropenem were 81.6%, 87.4%, 95.5%, and 98.7% respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 91.1%) and piperacillin-tazobactam (81.5% versus 97.3%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC90 for cefepime was 1 µg/ml for all species except E. cloacae (MIC90 4µg/ml). Conclusion: Between 2019-2024, 95.5% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.
Introduction: Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing minimum inhibitory concentration (MIC) distributions for ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods: MIC data for AmpC isolates between November 2019 to October 2024 were retrieved (BD Epicenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g., respiratory, wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2A-1). Descriptive statistics were computed and compared between moderate-risk AmpC inducers (MRAC) versus low-risk AmpC inducers (LRAC). Results: 5,631 isolates were analyzed, with 3,778 (67.1%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin-tazobactam, cefepime, and meropenem were 82.0%, 87.0%, 95.4%, and 98.7% respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 94.2%) and piperacillin-tazobactam (81.3% versus 98.6%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC90 for cefepime was 1 µg/ml for all species except E. cloacae (MIC90 4µg/ml). Conclusion: Between 2019-2024, 95.4% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.
Blastocystis hominis is a ubiquitous intestinal parasite commonly detected in human stools. Queries about the pathogenic nature of B. hominis in immunocompetent individuals have been raised with conflicting reports about the clinical significance of detecting the parasites in various specimens. Cases of invasive intestinal infections and identification of Blastocystis species in a splenic cyst and hepatic abscess have previously been reported. We present the case of a 65-year-old man with history of recent travel to a tropical country who was found to have multiple hepatic abscesses. Analysis of the hepatic abscess fluid confirmed the presence of Entamoeba species and B. hominis. To our knowledge, this is the second reported case in which B. hominis was identified with E. histolytica in a liver abscess, which may provide additional information about the infective potential of the parasite. However, further studies are required to confirm the pathogenicity of B. hominis, including molecular investigations into the various genetic subtypes.
29 October 2026 in Antimicrobial Stewardship & Healthcare Epidemiology
Background: AmpC B-lactamases cause resistance to broad-spectrum B-lactams with variable expression dependent on bacterial species. Practice remains heterogenous regarding treatment of infections caused by AmpC organisms. This study aimed to assess the impact of a microbiology comment-based stewardship intervention on the definitive treatment of low-risk AmpC-producing Enterobacterales bacteremia. Methods: This was a pre- and posttest quality improvement study conducted at Island Health Authority. A stewardship intervention involving amendment of a microbiology report comment regarding inducible resistance was implemented on February 13, 2023. Patients aged 18 and older with blood cultures growing low-risk AmpC-producing organisms were included. The primary end point of proportion of patients receiving ceftriaxone or piperacillin-tazobactam was compared between pre- (June 2021 to February 2023) and postintervention periods (February 2023 to October 2024). Secondary end points included clinical outcomes, ceftriaxone/piperacilin-tazobactam resistance rates, and C. difficile infection. Results: A total of 56 patients were included (25 preintervention and 31 postintervention). Definitive ceftriaxone/pipercillin-tazobactam antibiotic therapy was prescribed more frequently postintervention compared to preintervention (45.8% vs 5.0%, P < .001). After adjusting for critical illness, patients in the postintervention group had 17.7-fold higher odds (CI 1.9–162.6) of receiving definitive ceftriaxone or piperacillin-tazobactam (PTZ) compared to the preintervention group. No patients required retreatment for the same organism initially cultured, and neither group had ceftriaxone or PTZ resistance documented within 30 days posttreatment completion. Conclusion: The microbiology comment-based antimicrobial stewardship intervention led to increased ceftriaxone and PTZ prescribing for low-risk AmpC-producing Enterobacterales bloodstream infections compared to carbapenems, without affecting patient outcomes and increasing resistance rates.